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Peptide-Modified Dendrimer Nanoparticles for Targeted
Therapy of Colorectal Cancer
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Peptides have recently emerged as a promising class of targeting ligands for
specific drug delivery in cancer treatment, which avoid undesirable side effects
of the systemic administration of chemotherapeutics. Their conjugation with
nanoparticles has been demonstrated to improve the functionality of peptides
resulting in a versatile platform for biomedical applications. In this work, the
development of carboxymethylchitosan/poly(amidoamine) (CMCht/PAMAM)
dendrimer nanoparticles functionalized with YIGSR laminin receptor binding
peptide for the active targeting and specific delivery of therapeutic agents into
colorectal cancer cells is described. The successful functionalization is
confirmed by several physico-chemical characterization techniques. The
selectivity of the YIGSR-CMCht/PAMAM dendrimer nanoparticles is first
validated in vitro using a micropatterned array of 67 kDa laminin receptor.
Next, the specificity of YIGSR-CMCht/PAMAM dendrimers nanoparticles
toward laminin receptor is further confirmed both in 2D and 3D settings using
HCT-116 colorectal cancer cells and L929 fibroblasts in co-culture. Finally,
gemcitabine-loaded YIGSR-CMCht/PAMAM dendrimer nanoparticles induce
a targeted mortality on HCT-116 cancer cells in a co-culture scenario. Overall,
the study shows solid evidence that YIGSR laminin receptor binding peptide
coupled to CMCht/PAMAM dendrimer nanoparticles may be employed as an
anticancerous target for the specific and intracellular delivery of
chemotherapeutic agents.
1. Introduction
Cancer is a leading cause of death worldwide, with more
than 10 million new cases each year, and an estimation of
≈13.1million cancer-related deaths by 2030.[1] Typically, cytotoxic
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chemotherapies have a narrow therapeu-
tic window, with high peaks of plasma
concentration. This leads to high-dose
requirements with adverse side effects,
reduced therapeutic indices, nonspecific
targeting, and development of multiple
drug resistance.[2]
Nanotechnology has evolved as an excit-
ing platform in the field of cancer research
with promises to improve the pharma-
cology of current cancer therapeutics.[3]
Drug-loaded nanoparticles (NPs) offer
several advantages over free drugs. This
includes their capabilities to encapsu-
late large amounts of chemotherapeutic
agents, a prolonged half-life, and an in-
creased targeting efficiency leading to
reduced toxicity.[4] Nanoparticle size, core
properties, and surface modifications are
considered as key factors affecting the
clearance rate and organ distribution.[5]
A significant number of nanomaterials,
including inorganic nanoparticles, lipo-
somes, micelles, and polymers have been
developed for targeted drug delivery in
cancer.[6] Dendrimers are considered a
promising alternative because of their
advanced capabilities, which make them
ideal tools for targeted drug delivery. As an
example, they can increase the solubility and bioavailability of hy-
drophobic drugs.[7] Further, their architecture and availability of
active functional groups allow the easy addition of moieties and
the encapsulation of drugs.[7]
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Different types of active tumor-targeted ligands, such as
RGD peptide, folic acid, and transferrin, have been employed
in conjunction with NPs to specifically direct and enhance
drug accumulation in the tumor.[8] In particular, doxorubicin-
loaded HPMA-copolymer conjugated with GE11 oligopeptide
have been employed to specifically target colorectal cancer (CRC)
cells with EGFR overexpression. A high cellular uptake of the
doxorubicin-loaded NP was observed, achieving a selective re-
lease of the drug.[9] Similarly, a multifunctional nanosystem
based on methotrexate-loaded guar gum NPs functionalized
with folic acid (MTXFA-GGNP) has been employed to release
methotrexate at colonic pH values (6.8) in CRC. Interestingly,
the engineered NPs displayed preferential in vivo uptake in colon
tissue.[10] However, most of these approaches were mainly stud-
ied in 2D environments. In addition, these studies also lacked a
visual representation and analysis of NPs internalization in a co-
culture scenario, and importantly, their validation using native-
like 3D settings.
Despite all the efforts invested in the development of targeted
drug delivery systems for improved cancer therapeutics, their
performance is still limited for medical applications. New ap-
proaches are needed to target efficiently and precisely the cancer
cells. In this regard, the YIGSR laminin receptor binding pep-
tide has demonstrated to be a promising class of targeting lig-
and for specific drug delivery in cancer treatment. Cancer cells
from various sources express high levels of the 67 kDa laminin re-
ceptor (67LR),[11] including bile duct carcinoma, colorectal carci-
noma, cervical cancer, and breast carcinoma,[12] which are shown
to be correlated with tumor invasiveness.[13] Earlier work has
demonstrated that the laminin binding capacity of plasma mem-
branes isolated fromhuman invasive breast carcinomas is 50-fold
greater than that of membranes from benign lesions or normal
tissue.[14]
In this study, we hypothesize that the peptide sequence
YIGSR grafted onto carboxymethylchitosan/poly(amidoamine)
(CMCht/PAMAM) dendrimer NPs promotes specific and tar-
geted internalization into CRC cells.[15] To this end, we first
characterize the morphology and successful functionalization of
CMCht/PAMAM and YIGSR-modified CMCht/PAMAM den-
drimer NPs by AFM, TEM, DLS, and H1NMR. The selectivity of
the YIGSR-CMCht/PAMAM dendrimer nanoparticles was first
validated in vitro using a micropatterned array of 67 kDa laminin
receptor. Next, we investigate the effect of both types of den-
drimer NPs on the viability of HCT-116 CRC cells or L929 fibrob-
lasts. Next, the targeted internalization of the NPs is assessed in
a co-culture of HCT-116 CRC cells and L929 fibroblasts both in
traditional well plates (2D) or encapsulated within a 3D Matrigel
matrix.
2. Results and Discussion
2.1. Physico-Chemical Characterization of Dendrimer
Nanoparticles
We first investigated the attachment of the YIGSR peptide
on the dendrimer NPs surface via carbodiimide chemistry
(Figure 1A), and the morphology and size of both type of
NPs. STEM images revealed a monodisperse round-shaped
morphology (Figure 1B), which was confirmed by AFM
measurements (see Figure S1A, Supporting Information). These
results suggested the successful grafting of the peptide sequence,
which conferred the YIGSR-CMCht/PAMAM dendrimer NPs
a larger size. DLS was used to quantify the size of the NPs.
Figure 1C shows the peaks associated with both the CM-
Cht/PAMAM and YIGSR-CMCht/PAMAM dendrimer NPs. In
the former, two main peaks were obtained, which corresponded
to individual and aggregated NPs. The first peak provided the av-
erage size of the individual NPs as 54 ± 7 nm, whereas the sec-
ond one corresponded to NP aggregates with a much bigger size.
In contrast, YIGSR-CMCht/PAMAM dendrimer NPs displayed
three peaks. The first peak located around 6 nm corresponded
to unreacted PAMAM G1.5. The reason is that the first step in
the synthesis of the dendrimer NPs is increasing the generation
of the PAMAM-CT (G 1.5), which has a theoretical size equal to
the one provided by the peak, and therefore, this peak was as-
sumed to correspond to unreacted G1.5. The second peak located
around 130 ± 20 nm corresponds to the YIGSR-modified den-
drimer NPs. Finally, the last peak is associated with aggregated
NPs. Altogether, these results show that attachment of the pep-
tide significantly increased the size of the NPs by ≈2.5-fold with-
out affecting the NPs polydispersity index (PDI) with values of
0.29 and 0.37 for CMCht/PAMAM and YIGSR-CMCht/PAMAM
PDI, respectively.
Figure 1D shows the FTIR spectrum of the CMCht/PAMAM
and the newly modified YIGSR-CMCht/PAMAM dendrimer
NPs. The spectrum of the modified NPs shows an increase in
peak intensity at 1700 cm−1 attributed to the amide II and C─N
stretching vibrations.[16] This is an evidence of the presence of
amine groups as well as of the chemical bonding between the
CMCht/PAMAM and the peptide. Similarly, the 520 cm−1 free
amino acid peak and the 1120 cm−1 NH3 vibration appear after
NP modification.[11,17] Moreover, both NPs showed characteris-
tic peaks, such as the strong and broad peak of absorption at
≈3400 cm−1, which are assigned to the stretching vibration of
the structural N─H overlapping the O─H stretching. Similarly,
the attachment of the YIGSR peptide was further confirmed
by the analysis of the chemical signature obtained by H1NMR
(Figure 1E).[18] Bearing in mind the analysis of H1NMR spectra
(see Figure S2, Supporting Information), we can state that the sig-
nature protons of CH2 and CH3 of the YIGSR peptide are present
in the YIGSR-CMCht/PAMAM around 2 and 3 ppm, indicating
the successful grafting of the peptide.Moreover, the broad singlet
at 3.02 ppm of the CMCht/PAMAM is also present in the mod-
ified nanoparticles. Taken together, the results obtained indicate
that the peptide was successfully conjugated to the NPs.
We next measured the Zeta potential values of both unmod-
ified CMCht/PAMAM and YIGSR-modified CMCht/PAMAM
dendrimer NPs. Figure 1F shows that the formers have a value of
−14.7± 3.0mV inPBS and−34.3± 3.0mV in ddH20. In contrast,
YIGSR-modified CMCht/PAMAM dendrimer NPs have a value
of −9.3 ± 0.8 mV in PBS and −19.3 ± 0.8 mV in ddH20. The dif-
ference between YIGSR-modified dendrimer NPs (less negative)
and unmodifiedNPs (more negative), indicates a reduction in the
number of carboxylic acid groups on the NPs surface following
peptide binding. Moreover, the addition of the positively charged
arginine present in the peptide sequence suggests a successful
grafting. It is expected that CMCht has a good pH and ion sensi-
tivity in aqueous solution due to abundant ─COOH and ─NH2
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Figure 1. Physico-chemical characterization of dendrimer nanoparticles. A) Schematic representation of the dendrimer NPs modification with YIGSR
peptide from laminin via carbodiimide chemistry. B) STEM image of CMCht/PAMAM and YIGSR-CMCht/PAMAM dendrimer NPs. C) Representative
graphic of the particle size distribution of CMCht/PAMAM and YIGSR-CMCht/PAMAM NPs, showing that the peptide sequence conferred the NPs a
larger size. D) FTIR analysis of CMCht/PAMAM and YIGSR-CMCht/PAMAM dendrimer NPs, showing an increase in intensity of the bands at 1700
cm−1 for YIGSR-CMCht/PAMAM dendrimers. E) H1NMR spectra of YIGSR-CMCht/PAMAM, CMCht/PAMAM, and YIGSR. The YIGSR-CMCht/PAMAM
shows a peak at 3 ppm and no peak at 4.3 ppm suggesting that the substitutions occurred mainly on the C2 amino group of CMCht. F) Table of the
mean NP diameter and Zeta potential in PBS and ddH20, showing an increase in diameter and a decrease in Zeta potential upon the addition of YIGSR.
G) Determination of peptide concentration by protein quantification (BCA protein quantification) in CMCht/PAMAM and YIGSR-CMCht/PAMAM.
groups. On the other hand, since the Zeta potential of NPs is
determined by their surface properties, this data shows the neg-
atively charged carboxymethyl groups in the CMCht/PAMAM
dendrimer NPs. The different Zeta potential values obtained in
ddH20 and PBS can be explained by the fact that the CMCht be-
haves as a weak polyanionic polyelectrolyte at physiological pH,
that is, the amino groups are not protonated andmost of carboxyl
groups are not dissociated.
Further characterization was achieved by quantifying the
amount of coupled peptide using the BCA protein quantifi-
cation assay and compared to a standard curve using BSA
(Figure 1G). Results show a significant difference between
the levels of protein on non-modified and YIGSR-grafted CM-
Cht/PAMAM dendrimer NPs. The former shows an amount of
3.60 ± 1.62 µg mL−1, whereas the later has a concentration of
71.00 ± 3.75 µg mL−1. This indicates that the peptide sequence
YIGSR is successfully attached to the dendrimer NPs. Finally,
the presence of the peptide on the CMCht/PAMAM dendrimer
NPs was investigated by UV spectroscopy (Figure S1B, Support-
ing Information). The peptide sequence YIGSR incorporates the
amino acid tyrosine, which exhibits two characteristic absorbance
peaks in the UV spectral region at ≈230 nm and 280 nm.[19] The
UV spectra were obtained using CMCht/PAMAM and modified
YIGSR-CMCht/PAMAM dendrimer NPs for comparison. Two
peaks located around 275 nm were observed. This indicated that
the peptide is effectively grafted to the polymer backbone.
2.2. Targeted Detection of FITC-YIGSR-CMCht/PAMAM on a
Micropatterned Laminin Receptor Array
The 67 kDa high affinity LR is a non-integrin cell surface recep-
tor of the extracellular matrix. The expression of this receptor is
thought to be increased in neoplastic cells, which directly corre-
lates with an enhanced invasiveness and metastatic potential.[20]
To confirm this higher expression, we first performed an im-
munocytochemistry analysis to assess qualitatively the differ-
ences in LR expression in HCT-116 and L929 cells at 24 h and
72 h. HCT-116 cells displayed round morphologies and prolif-
erated forming dense aggregates (Figure 2A). In contrary, L929
fibroblasts showed highly spread phenotypes. Importantly, HCT-
116 displayed a large LR signal both at 24 h and 72 h. This is in
contrast to L929 fibroblasts, which showed a low LR expression.
Taken together, these results suggest that the 67 kDa LR may be
employed as a cancer-specific target to specifically deliver drug-
loaded YIGSR-CMCht/PAMAM dendrimer NPs in a precise and
efficient manner.
Next, we evaluated in vitro the specificity of the YIGSR-
CMCht/PAMAM dendrimer NPs toward the LR. For this, an
array of 67 kDa LR was micropatterned on a functionalized
glass coverslip by micro-contact printing to recreate in vitro
the physiological target (Figure 2B). Next, FITC-labeled YIGSR-
CMCht/PAMAM dendrimer NPs were incubated on top of the
LR array. We observed that the FITC-labeled NPs attachedmainly
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Figure 2. Specificity of FITC-YIGSR-CMCht/PAMAM dendrimer NPs on a micropatterned LR array. A) Immunocytochemistry of anti-67 kDa LR (green)
performed on a co-culture of HCT-116 CRC cells and L929 fibroblasts (stained in red; see Figure S3, Supporting Information) cells at 24 and 72 h. An
overexpression of LR onHCT-116 is visible at both time points. B) (Left) Schematic representation of the steps involved in themicrocontact printing of the
LR: i) incubation of the PDMS stamp with the LR solution; ii) microcontact printing of the LR on top of a functionalized (APTES 5% and glutaraldehyde)
glass coverslip; iii) PDMS stamp removal and rinsing with ddH2O; iv) incubation with FITC-YIGSR-CMCht/PAMAM; and v) rinse with ddH2O to remove
the excess of FITC-YIGSR-CMCht/PAMAM. (Right) Representative brightfield and fluorescence microscopy images of the PDMS stamp and FITC-YIGSR-
CMCht/PAMAM NPs array displaying the triangular micro-sized LR features. Scale bar: 100 µm.
on top of the triangular micropatterned regions, which contained
the 67 kDa LR protein. Overall, these results show a strong affin-
ity of between the NPs grafted with a portion of YIGSR peptide
and the LR protein. However, more complex experiments involv-
ing protein receptors other than LR may need to be also tested to
univocally prove a really specific affinity for this receptor.
2.3. Cytotoxicity Tests: Metabolic Activity and Cell Proliferation
The cytotoxicity of the dendrimer NPs was assessed by measur-
ing cell metabolic activities and proliferations by means of Ala-
mar blue and DNA quantification assays. HCT-116 cancer cells
and L929 fibroblasts were exposed to CMCht/PAMAM, YIGSR-
CMCht/PAMAM, and GEM-YIGSR-CMCht/PAMAM at a final
concentration of 0.5 mg mL−1 over a period of 72 h. This value
was selected taking into consideration the maximum concen-
tration of pure dendrimer NPs (i.e., non-modified) that may
be employed without observing any cytotoxic effect.[15] It is im-
portant to notice that both the metabolic activity and cell via-
bility were assessed in monoculture to discard the possibility
of inherent toxicities of non-modified and modified dendrimer
NPs. Both HCT-116 cancer cells and L929 fibroblasts signifi-
cantly proliferated from day 1 to day 3 in the absence (control)
and presence of CMCht/PAMAM and YIGSR-CMCht/PAMAM
NPs (Figure 3). The obtained results showed no deleterious
effects of the non-modified CMCht/PAMAM and the YIGSR-
CMCht/PAMAM dendrimer NPs on cell viability and prolifer-
ation in both cell types. This indicates that the grafting of the
YIGSR sequence did not significantly affect cellular behavior.
Conversely, GEM-loaded YIGSR-CMCht/PAMAM NPs had a
clear cytotoxicity in both cell types due to the release of the drug,
as demonstrated by the decrease in the metabolic activity and
DNA amount (Figure 3A,B). Interestingly, this effect was mostly
observed at early time points in HCT-116 cancer cells in contrast
to L929 fibroblasts, where the cytotoxicity was only observed at
72 h. This suggests that the drug was internalized faster in HCT-
116 cancer cells due to LR overexpression. For L929 fibroblasts,
viability was most likely affected by the release of GEM from the
NPs. Regarding the release of GEM from the NPs, and its poten-
tial in vivo side effects, it is plausible that the NPs release some
amount of drug in the medium before it is internalized by the
cells. However, its effect should not be significant because the
same conditions and time points were tested in co-culture (sim-
ilar to in vivo scenario) with an increased cell death for HCT-
116 cancer cells. Overall, we do not anticipate any significant ad-
verse effect of the released drug, within the range of the used
concentrations, on noncancerous cells when eventually used in
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Figure 3. Cytotoxicity studies. A) Metabolic activity determined by Alamar blue, and B) DNA quantification results of HCT-116 cancer cells and L929
fibroblasts in the presence of 0.5 mg mL−1 of CMCht/PAMAM, YIGSR-CMCht/PAMAM, and GEM-loaded YIGSR-CMCht/PAMAM, at 24, 48, and 72 h.
*Significant differences when comparing the different conditions with control (0 mg mL−1) at each time point. #Significant differences were observed
when comparing to CMCht/PAMAM at each time point. $Significant differences were observed when comparing to YIGSR-CMCht/PAMAM at each time
point. p < 0.05.
vivo. Moreover, it is worth noticing that these effects were ob-
served when HCT-116 and L929 were cultured in separate, and
not in co-culture. Only after assessing the noncytotoxic effects of
the peptide modification in monoculture, its effect in co-culture
was investigated. Overall, these results indicate that GEM-loaded
YIGSR-CMCht/PAMAMNPs affected the viability and prolifera-
tion of HCT-116 cancer cells and L929 fibroblasts in contrast to
non-modified and peptide-grafted dendrimer NPs, but in differ-
ent time scales.
2.4. Targeted Internalization of Dendrimer Nanoparticles
in 2D and 3D
We next investigated whether the attachment of YIGSR on
the surface of the dendrimer NPs influenced their preferen-
tial uptake by HCT-116 cancer cells, which overexpress 67 kDa
LR at their surface, in a co-culture with L929 fibroblasts (see
Figure 4A). Nanoparticle internalization was first investigated in
2D. As expected, FITC-CMCht/PAMAMNPs widely internalized
in both cell types at 24 h and 72 h, and localized in the cyto-
plasm and around the nucleus[15,18] (Figure 4B) mainly. In con-
trast, the peptide-modified YIGSR-CMCht/PAMAM dendrimer
NPs internalized preferentially into HCT-116 cancer cells (red)
at 24 h when seeded in a co-culture with L929 fibroblasts (blue).
Importantly, a qualitative increase in the number of internalized
NPs could be observed from 24 h to 72 h. This suggested that
peptide-grafted NPs were specifically targeted toward HCT-116
cells overexpressing 67 kDa LR.
We next used an in-vivo-like 3D scenario to determine the
efficiency of the cellular uptake mediated by the targeted inter-
action of the YIGSR peptide with the LR. For this, we encapsu-
lated HCT-116 cancer cells and L929 fibroblasts into a 3D matrix
of Matrigel. Figure 4B (bottom) shows the cells cultured in the
absence (control) and presence of CMCht/PAMAM and YIGSR-
CMCht/PAMAM dendrimer NPs. We first investigated whether
theNPswere capable to diffuse across themeshes of the hydrogel
and target the HCT-116 cells. After 24 h, no significant internal-
ization of both CMCht/PAMAM and YIGSR-CMCht/PAMAM
NPs was observed (data not shown). Instead, the NPs aggregated
in the outer membrane of the cells (see Figure S1E, Support-
ing Information). This phenomenon may be a consequence of
NPs diffusing through the dense mesh of the crosslinked hy-
drogel, and therefore, taking longer than in 2D to interact with
cells and internalize. In contrast, after 72 h, FITC-labeled NPs
spread all across the 3D hydrogel accumulating both inside and
around the HCT-116 cells. Notably, it was found that YIGSR-
CMCht/PAMAM NPs internalized preferentially into the HCT-
116 cancer cells (Figure 4B(1), white arrowheads). In contrast,
L929 fibroblasts did not show any significant evidence of NPs
internalization (see Figure 4B(2)). These results highlight the
differences between 2D and 3D scenarios in drug delivery appli-
cations, even in terms of simple biological processes such as the
internalization of NPs.
We next quantified the amount of NPs that were internal-
ized in both conditions (2D vs 3D). To this end, flow cy-
tometry analysis was performed using the same experimental
conditions. HCT-116 cancer cells were stained with an anti-CD44
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Figure 4. Internalization of dendrimer nanoparticles. A) Schematics of the different conditions studied. B) Confocal microscopy images of HCT-116
cancer cells (red) and L929 fibroblasts (blue) co-culture in the presence of YIGSR-CMCht/PAMAM and CMCht/PAMAM dendrimer NPs in (top) 2D
for 24 and 72 h, and (bottom) in 3D for 72 h. In the latter, (1) and (2) show a higher magnification of HCT-116 and L929 cells, respectively, showing
the internalization of YIGSR-CMCht/PAMAM dendrimer NPs exclusively for HCT-116 (observed only with the 488 nm filter). Inset images show a more
detailed view of the NPs (indicated by white arrowheads). C) Flow cytometry results of NPs internalization in co-culture in both 2D and 3D for 24 and
72 h. Scale bars: 20 µm.
antibody-PE (see Figure S1C, Supporting Information). In this
case, only the HCT-116 cells were stained, serving as a differ-
ential marker. The obtained results were in agreement with the
fluorescence microscopy results. In 2D, a maximum internaliza-
tion of NPs (96.27%) for the HCT-116 cells was observed at 24 h,
compared to the low internalization (2.97%) in L929 fibroblasts
(Figure 4C, left). At 72 h, the internalization of NPs increased
slightly (98.45% for HCT-116 cancer cells and 6.56% for L929 fi-
broblasts). This clearly showed the lower levels of internalization
in L929 fibroblasts when compared to those of HCT-116 cancer
cells. In contrast, in 3D scenario, we found that the overall levels
of internalization were not as high as in 2D (Figure 4C, right).
After 24 h, the level of internalization of targeted NPs in HCT-
116 cancer cells and L929 fibroblasts was 65.52% and 3.54%,
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Figure 5. Cell viability of HCT-116 cancer cells and L929 fibroblasts in the presence of GEM-YIGSR-CMCht/PAMAM dendrimers. A) Live/dead assay
performed on a co-culture of HCT-116 cancer cells (unstained) and L929 fibroblasts (in blue) at 24 and 72 h in 2D. B) Flow cytometry analysis of cell
viability in the presence of GEM-YIGSR-CMCht/PAMAM in a co-culture of HCT-116 (CD44 positive) and L929 cells (CD44 negative cells).
respectively. At 72 h, these values increased up to 85.44% and
9.95%, respectively. As mentioned previously, these differences
between 2D and 3D may be related to the fact that in 3D den-
drimer NPs need to diffuse through the dense hydrogel mesh to
target the encapsulated cells.
Together, these results indicate a targeted internalization of
YIGSR-CMCht/PAMAM dendrimer NPs toward HCT-116 cells
overexpressing 67 kDa LR both in 2D and 3D. However, differ-
ent levels of internalization levels were obtained when compar-
ing both conditions, reinforcing that traditional 2D models may
poorly correlate with human disease states.
2.5. Targeted Gemcitabine Delivery Using Dendrimer
Nanoparticles in 2D and 3D
After verifying the targeted and preferential internalization of
YIGSR-CMCht/PAMAM NPs toward HCT-116 cancer cells, we
next investigated the gemcitabine (GEM) release from YIGSR-
CMCht/PAMAM in a co-culture of HCT-116 cancer cells and
L929 fibroblasts in 2D and 3D.[21] In a previous work, we demon-
strated an encapsulation efficiency ofGEM intoCMCht/PAMAM
NPs of 52.99% ± 3.50%, with a drug-loading efficiency of
9.42% ± 3.50%.[22] First, the viability of cells was analyzed by
live/dead assay in a 2D co-culture at 24 h and 72 h in the pres-
ence of GEM-YIGSR-CMCht/PAMAM (Figure 5A). The results
show that L929 fibroblasts (in blue) were not substantially af-
fected by the GEM-YIGSR-CMCht/PAMAM NPs; they were co-
stained in blue and in green (live cells). In contrast, HCT-116
cancer cells (unstained) displayed a largermortality at 24 h (red—
dead cells) (Figure 5A) indicating a specific GEM release inside
these cells. It is worth noticing that most of the cancer cells were
alive at 24 h. However, they displayed an elongated—perturbed—
phenotype with the appearance of blebs, which suggested the
beginning of the apoptotic process.[23] In contrast, this was not
observed in L929 cells. This was more stringent at 72 h, where
mainly HCT-116 cancer cells were dead. In contrast, L929 were
mostly alive, displaying a morphology consistent with its normal
phenotype and not significantly perturbed. We confirmed these
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qualitative observations by quantifying the amount of live/dead
cells by flow cytometry. For this, CD44-FITC was used to label
HCT-116 cancer cells, while L929 fibroblasts were CD44 nega-
tive and PI labeled the dead cells. Figure 5B shows a 4.70% of
cell death (PI staining) in the CD44 positive population (HCT-
116) in 2D at 24 h, and 3.44% for the CD44 negative population
(L929). Although not very substantial at such early time point,
there is a difference between both cell death values, being higher
for cancer HCT-116 cells. The same trend was observed in 3D,
where cell death for the CD44 positive (HCT-116) and negative
(L929) populations was 30.16% and 26.07%, respectively. Note
that the percentage of overall cell death is higher in 3D than in
2D. This phenomenon could be related to the process of retriev-
ing cells from the hydrogel. This process consists of leaving the
hydrogels in the recovery solution at 4 °C for at least 30 min. This
may damage the cells, and therefore, may explain the increase in
percentage of cell death.
At 72 h, we observed a high level of internalization inHCT-116
cancer cells in 2D compared to L929 fibroblasts. This resulted in
a significantly higher level of cell death (68.72%) observed in the
CD44 positive population (HCT-116) compared to L929 fibrob-
lasts (3.20%); this was in agreement with the previously studied
internalization phenomena. In 3D, after exposing the co-culture
to GEM-YIGSR-CMCht/PAMAM for 72 h, cell death percentage
of the CD44 positive population (HCT-116) was 31.15%, while
for the CD44 negative population (L929) was 19.52%. These re-
sults show that the intracellular release of GEM was successfully
achieved mainly toward cancer cells. However, when comparing
the same condition at 24 h, we observed that the level of cell death
did not increase significantly. This could be explained by several
possible factors: i) the GEM is released within the first 24 h, be-
ing almost 40% released in the first 6 h of culture.[22] Since a static
culture is employed and freshmedium is not added, the drug lev-
els are stable, therefore, cell death is also stable both at 24 h and
72 h; ii) internalization rates do not drastically increase from 24 h
to 72 h in 3D. This also corroborates the fact that there is no sig-
nificant difference in the amount of drug available inside the cells
to induce apoptosis from 24 h to 72 h; and iii) at 72 h, cells seem
to be in the beginning of the process of apoptosis (Figure 5A), as
suggested by the presence of both green and red signals. This
also suggests that HCT-116 cancer cells may take longer time
to complete the cell death process and to be detected by flow
cytometry.
Taken together, these results suggest the successful targeting
and release of the GEM-YIGSR-CMCht/PAMAM dendrimers
NPs into the HCT-116 cells taking advantage of the 67 kDa LR
overexpression on the cell surface.
Finally, the rationale of using YIGSR (a peptide derived from
laminin) as a tumor targeting is based on the solid evidences
that the levels of expression of the 67 kDa LR directly corre-
late with the invasiveness and metastatic potential in numerous
tumors.[13,14,24] It is our goal to further test these newly developed
NPs using primary colorectal cancer cells and noncancerous col-
orectal cells in a dynamic microfluidic system, in order to better
mimic the native scenario.
Overall, the future perspective of targeted NPs for cancer
research is promising. Several formulations currently under pre-
clinical and clinical studies for CRC may soon reach the mar-
ket. A future challenge common to recent technologies, with no
exception for targeted NPs, is the need for implementation of sys-
tems or protocols to determine the molecular expression profile
of tumors from patients with CRC. Its classification according
to the genetic profile, stage of tumor development, and putative
targeting molecules is imperative.[25] By achieving this, the ratio-
nal administration of precise-targeted nanomedicines containing
the most effective drug combination may revolutionize the way
cancer is treated.
3. Conclusion
The conjugation of ligands, such as peptides, aptamers, and other
small molecules (e.g., antibodies) on the surface of NPs for cell
targeting has resulted in a new generation of NPs for cancer
therapy with enhanced in vitro and in vivo specificity. This work
demonstrates the development of YIGSR-CMCht/PAMAM den-
drimer NPs. Its specificity toward the 67 kDa receptor protein
was first demonstrated in vitro by means of a micro-pattern as-
say. Next, we showed that YIGSR-CMCht/PAMAM dendrimer
NPs preferentially targeted HCT-116 cancer in a co-culture with
L929 fibroblasts, specifically releasing the anticancer drug intra-
cellularly. These novel NPs demonstrated that they may be con-
sidered as a promising tool for targeted drug delivery in CRC
and other cancer types with high levels of the 67LR. In the fu-
ture, such technology will need to be evaluated in other CRC
cell lines and primary cells to fully disclose the potential of
YIGSR-targeted NPs in cancer therapeutics. Finally, the poten-
tial of YIGSR-CMCht/PAMAM NPs for further applications is
immense. This tool may bring closer to a clinical and pharma-
ceutical translatable setting for continuing research.
4. Experimental Section
4.1. Synthesis of the CMCht/PAMAM Dendrimer Nanoparticles
Dendrimer NPs were fabricated as described elsewhere.[15] Briefly, using a
chemical modification route of chitin (Sigma, Germany), we synthesized
CMCht with a degree of deacetylation of 80% and a degree of substitu-
tion of 47%. CMCht/PAMAMdendrimer NPs were prepared in a step-wise
manner as follows: first, the increase of the dendrimers’ generation was
carried out. An appropriate volume of PAMAM-CT (G 1.5) inmethanol was
transferred to a volumetric flask. The starting compound was re-dissolved
in ultrapure water to give a final concentration of 10 mg.mL−1. The pH
was adjusted to 6.5 with dilute hydrochloric acid solution (Riedel de-Haen,
Germany). 1-Ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride
(EDC, Fluka, Portugal) was then added to the solution at a molar ratio
sufficient to modify the carboxylate residue of the dendrimers. The solu-
tion was kept under agitation for 30 min at room temperature. Ethylenedi-
amine (EDA, Sigma, Germany) was added to the solution at a molar ratio
equal to that of EDC and left to react for 4 h. After this period, the excess
of EDC was removed by dialysis (cellulose tubing, benzoylated for separat-
ing compounds with a MW ≤1200, Sigma, Germany). After preparing the
PAMAM-amine terminated compound, an exhaustive alkylation of the pri-
mary amines (Michael addition) was performed. An appropriate volume of
PAMAM-amine terminated was mixed with methanol (Sigma, Germany)
and methyl methacrylate. CMCht/PAMAM dendrimer NPs were then pre-
cipitated after addition of an appropriate volume of a saturated Na2CO3
(Sigma, Germany) solution and cold acetone (Pronalab, Portugal).
Precipitates were collected by filtration and dispersed in ultrapure water
for dialysis over a period of 48 h. Finally, CMCht/PAMAM dendrimer NPs
were obtained by freezing the solution at −80 °C and freeze-dried (Telstar-
Cryodos-80) for 7 days.
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4.2. Peptide Attachment onto CMCht/PAMAM Dendrimer
Nanoparticles
The attachment of YIGSR peptide (Genscript Corp, Piscataway, NJ, USA)
to the NPs was performed via carbodiimide chemistry to form an amide
bond between the carboxyl groups on the NPs and the amine groups at
the YIGSR N-terminal end group.[26] CMCht/PAMAM 1% was prepared in
buffer 2-(N-morpholino)ethanesulfonic acid) (MES, Sigma Aldrich, Ger-
many), and mixed with the appropriate amount of NHS-Sulfo, EDC, and
a 10 mg mL−1 YIGSR peptide solution (dissolved in MES buffer). The so-
lution was stirred for 24 h and the NPs were recovered by dialysis against
ultrapure water for 48 h followed by freeze-drying process for 7 days.
4.3. Labeling of CMCht/PAMAM Dendrimer Nanoparticles with
FITC
The conjugates of CMCht/PAMAM-FITC were obtained by covalently
bonding the CMCht amine group and the isothyocianate group of FITC
(10mgmL−1) (Sigma, Germany) in anhydrous dimethyl sulfoxide (DMSO,
Norconcessus, Portugal) creating a thiourea bond. First, a 10 mg mL−1
CMCht/PAMAM dendrimer NPs solution was prepared in a carbonate–
bicarbonate coupled buffer at pH 9.2. Then, a solution of FITC/DMSOwas
added under agitation and kept in the dark at 4 °C for 8 h. Next, the FITC-
labeled CMCht/PAMAM dendrimer NPs solution was dialyzed against ul-
trapure water for 24 h to remove unlinked FITC and filtered (pore size
<220 nm) in sterile and dark conditions. The final product was obtained
after freeze-drying.
4.4. Gemcitabine Incorporation into CMCht/PAMAM Dendrimer
Nanoparticles
Gemcitabine (GEM) was encapsulated in the NPs by mixing an aqueous
solution of YIGSR-CMCht/PAMAM dendrimer NPs with an aqueous GEM
solution with a final concentration of 5 × 104 m. Saturated sodium carbon-
ate solution (Na2CO3) and acetone was then added to the mixture. The
resulting precipitates were dialyzed against ultrapure water. GEM-loaded
YIGSR-CMCht/PAMAMdendrimer NPs were obtained by freezing the final
solution at −80 °C and freeze-drying the samples
4.5. Characterization of the CMCht/PAMAM Dendrimer
Nanoparticles
4.5.1. Protein Quantification
The concentration of YIGSR peptide grafted onto the dendrimer NPs
was estimated by UV spectroscopy (between 200 and 275 nm) and the
Micro-BCA (562 nm) protein quantification assay using a microplate
reader (BIO-TEK, EUA). Samples of CMCht/PAMAM andmodified YIGSR-
CMCht/PAMAM dendrimer NPs were dissolved in ultrapure water at a
final concentration of 1% and compared to standards for protein quantifi-
cation in triplicates.
4.5.2. Dynamic Light Scattering (DLS)
Zeta potential and the size of the CMCht/PAMAM and YIGSR-
CMCht/PAMAM dendrimer NPs were measured in a particle size an-
alyzer (Zetasizer Nano ZS, Malvern Instruments, UK). Particle size
analyses were performed by DLS in phosphate buffered saline (PBS) at pH
7.4 with low concentration of NPs and using disposable sizing cuvettes.
Electrophoretic determinations of Zeta potential were investigated using
the universal “dip” cell at pH 7.4 in PBS solution. Zeta potential was also
investigated in water.
4.5.3. Nuclear Magnetic Resonance Spectroscopy (NMR)
The structure of CMCht/PAMAM and YIGSR-CMCht/PAMAM dendrimer
NPs was determined by H1NMR. Both types of NPs were dissolved in
deuterated water (D2O). Then, the NMR spectra were obtained with a
Mercury-400BB operating at a frequency of 399.9 MHz at 50 °C. The 1D
1H spectra were acquired using a 45° pulse, a spectral width of 6.3 kHz,
and an acquisition time of 2.001 s.
4.5.4. Scanning Transmission Electron Microscopy (STEM)
Dendrimer NPs morphology was investigated by STEM (Philips CM-12,
FEI, The Netherlands), equipped with aMEGA VIEW-II DOCU camera and
Image Software Analyzer SIS NT DOCU. For this, the NPs were stained
with 2% of phosphotungstic acid and placed on the copper grids for ob-
servation.
4.5.5. Fourier Transform Infrared (FTIR)
The dried dendrimerNPs, prior to and after YIGSR attachment, weremixed
with KBr (sigma) and placed between two disks. Pressure was applied
(4.5 metric tons, Carver Inc.) on the disk to form a pellet. The spectrum of
the formed pellet was measured by FTIR spectroscopy (Exuinox 55, Bruker
Optics Inc., USA) in the range of 400–3500 cm−1.
4.5.6. Microcontact Printing
Poly(dimethylsiloxane) (PDMS) (1:10 w/w, Sylgard 184; Dow Corning)
stamps were replicated from an SU-8 mold (MicroChem) fabricated by
UV-photolithography (MIDAS MDA-400MA). The PDMS stamp was ren-
dered hydrophilic by plasma treatment to maximize 67 kDa LR pattern-
ing. Glass coverslips were plasma-treated for 1 min and incubated for
1 h under anoxic conditions in anhydrous methanol solution of 5%
(3-aminopropyl) triethoxysilane (APTES; Sigma Aldrich, Germany). Next,
the samples were washed with methanol followed by ultrapure water.
Then, APTES-functionalized coverslips were incubated for 30 min in a so-
lution of 1% gluteraldehyde (Sigma Aldrich, Germany) in ultrapure wa-
ter. The micropatterned PDMS stamp was incubated with 10 µg mL−1 LR
protein (Abcam, Portugal) solution for 2 h and the excess was removed
by nitrogen drying. Immediately, the PDMS stamp containing the LR was
placed in contact with the functionalized glass coverslip for 5 min. After
releasing the stamp, FITC-labeled YIGSR-CMCht/PAMAM dendrimer NPs
were incubated overnight.
4.6. In Vitro Cell Culture in 2D and 3D
4.6.1. Cell Culture
Human HCT-116 colorectal cancer cells and L929 fibroblasts were ob-
tained from the American Collection of Cell Cultures (ATCC, USA).
Cells were grown in Dulbecco’s Modified Eagle Medium (Sigma Aldrich,
Germany) supplemented with 10% fetal bovine serum and 1% peni-
cillin/streptomycin (Gibco, USA) at 37 °C and 5% CO2. Subcultures of
cells were performedwhen confluence reached values of≈90%. Then, cells
were plated at an initial density of 1 × 104 cells per well in a 24-well plate
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for metabolic activity and DNA quantification. Co-cultures were used for
internalization studies (1 × 104 of each cell type in 24-well plates).
4.6.2. Immunocytochemistry
L929 were pre-stained in red with CellTracker CM Dil (1 µm) and seeded
at an initial density of 1 × 104 cells per well in a 24-well plate. At days 1
and 3, HCT-116 cancer cells and L929 fibroblasts in co-culture were fixed
with 4% formalin (Sigma Aldrich, Germany) for 10 min and washed with
PBS. Cells were permeabilized with 0.1% Triton X-100 (Sigma Aldrich, Ger-
many) in PBS for 5 min and blocked with 3% BSA (Sigma Aldrich, Ger-
many) in PBS for 30 min. Immunolabeling was performed using a rabbit
antihumanmonoclonal antibody against 67 kDa LR (Abcam, 1:200) as pri-
mary antibody, prepared in PBS 1% BSA and incubated overnight at 4 °C.
The samples were incubated for 1 h at RT with the respective secondary
fluorochrome-conjugated antibodies, anti-rabbit/mouse IgG (Invitrogen,
dilution 1:1000). Immunofluorescence was observed under transmitted
fluorescence microscopy (Zeiss, Germany) (LR in green: ex/em 488/517;
Cell Tracker CM Dil in red: ex/em 594/618).
4.6.3. Metabolic Activity
Alamar blue (AB) assay was performed according to supplier’s in-
structions to assess the metabolic activity of cells. The effect of CM-
Cht/PAMAM, YIGSR-CMCht/PAMAM, and GEM-YIGSR-CMCht/PAMAM
dendrimer NPs was assessed in terms of metabolic activity in each cell
type separately. After 24 and 72 h in culture, specific cell culture medium
containing 20% v/v ABwas added to the different culture wells. The system
was incubated for 4 h after which fluorescence was monitored at 590 nm
emission wavelength (excitation wavelength 530 nm), using a microplate
reader (FL 600, Bio-Tek Instruments). After each AB determination, cells
were rinsed with PBS and fresh culture medium was added to continue
the culture. Medium with 20% v/v AB was used as a blank.
4.6.4. DNA Quantification
To assess the effect of CMCht/PAMAM, YIGSR-CMCht/PAMAM, and
GEM-YIGSR-CMCht/PAMAM dendrimer NPs on cancer cells and fibrob-
lasts separately, the total amount of DNA was measured using the flu-
orimetric double-stranded DNA (dsDNA) quantification kit (Quant-iT
PicoGreen dsDNA Assay Kit, Molecular Probes). The cells were washed
with sterile PBS and lysed with 1 mL of ultrapure water in each well. The
cellular suspensions were transferred into microtubes, incubated in a wa-
ter bath at 37 °C for 1 h, and stored at −80 °C for further analysis. DNA
standards were prepared with concentrations varying between 0 and 2 µg
mL−1. Next, 28.7 µL of sample (or DNA standard), 71.3 µL of PicoGreen,
and 100 µL of TE buffer were mixed in each well of an opaque 96-well plate
(Alfagene, Portugal), according to the manufacturer’s protocol. Next, after
10 min incubation at RT, fluorescence was measured using an excitation
and emission wavelengths of 485 and 528 nm, respectively. Sample DNA
values were read off from DNA standard curve.
4.6.5. Live/Dead Assay
The cell viability was assessed by calcein-AM and propidium iodide (PI;
Life Technologies, Carlsbad, CA, USA) staining. L929 fibroblasts were
first stained with CellTracker Blue CMAC (Alfagene, Portugal), whereas
HCT-116 cells were left unstained. After 72 h, three samples were incu-
bated in 1 µg·mL−1 calcein-AM and 5 µg·mL−1 PI prepared in DMEM
low glucose supplemented with sodium bicarbonate and 1% v/v antibi-
otic/antimycotic solution for 30 min in the dark at 37 °C in 5% CO2.
After PBS washing, samples were immediately analyzed in the confocal
microscopy (Calcein-AM in green: ex/em 495/515 nm; PI in red: ex/em
495/635 nm; CellTracker Blue CMAC in blue: ex/em 353/466 nm) (Leica,
SP8, Germany).
4.6.6. Cellular Uptake
HCT-116 colorectal cancer cells and L929 fibroblasts were pre-stained in
Far Red and in Blue CMAC CellTracker (Alfagene, Portugal), respectively.
After 30 min incubation at 37 °C, cells were seeded in co-culture at a den-
sity of 1 × 104 cells (each type)/well in 24-well plates, and allowed to ad-
here overnight. Then, the culture medium was replaced by fresh one sup-
plemented with FITC-CMCht/PAMAM and FITC-YIGSR-CMCht/PAMAM
dendrimer NPs at a final concentration of 0.5 mg mL−1. At 24 and 72 h,
cells were washed with PBS, fixed with 4% formalin for 20min at RT,
washed three times with PBS, and permeabilized with 0.2% Triton X-100
in PBS for 10 min. Next, cells were washed with PBS. The cell nuclei were
stained with DAPI and F-actin with Phalloidin, as described above. The
cells were imaged by confocal microscopy to assess the internalization of
NPs (FITC – 488 nm). For 3D studies, the same procedure was used. In
this case, the cells were encapsulated into a 50 µL Matrigel matrix (Enzi-
farma, Portugal).
4.6.7. Flow Cytometry Analysis
For internalization analysis, the cells were co-cultured in medium supple-
mented with 0.5 mg mL−1 of FITC-labeled YIGSR-CMCht/PAMAM den-
drimer NPs in 24-well plates (1 × 104 cells; each type/well). Cells cultured
in complete culture medium were used as controls. After 24 and 72 h, the
cells were trypsinized (TrypleX, Life technologies, USA) and a cell strainer
was used to avoid cell clusters. Next, 0.5 mL of DMEM complete medium
was added to each well and the samples were transferred to flow cytom-
etry tubes. To distinguish cells in co-culture, 10 µL of PE-CD44 antibody
(Abcam, Portugal) was incubated with HCT-116 cells for 20 min at RT. Af-
ter washing with 2 mL of 2% FBS in PBS, the tubes were centrifuged at
300 rpm for 5 min and re-suspended in 1% formalin in PBS. The cell sus-
pensions were analyzed in FACSCalibur flow cytometer (BD Biosciences,
USA). A similar approach was followed for cell viability studies. In this
case, the tubes were centrifuged at 300 rpm for 5 min and HCT-116 were
stained with FITC-CD44 (Abcam, Portugal) for 30 min and re-suspended
in 2% FBS in PBS. Then, 1 µL of PI was added to the cell suspensions and
incubated for 10 min at RT, and analyzed by FACSCalibur flow cytometer.
For internalization and cell viability assays in 3D, cells encapsulated inMa-
trigel were retrieved using 500 µL of Corning Cell Recovery Solution (Corn-
ing, USA) for 30 min at 4 °C and the subsequent protocol was performed
as previously described.
For all assays, calibrate beads three-color kit (BD CaliBRITE beads,
USA) was used to adjust the instrument settings before samples are run
on the flow cytometer. Finally, data were analyzed using the Flowing Soft-
ware 2.
4.6.8. Statistical Analysis
Statistical analysis was performed using GraphPad Prism 5.0 software ver-
sion 5.0a. The nonparametric Mann–Whitney test was used to compare
two groups, whereas comparison between more than two groups was per-
formed using the Kruskal–Wallis test followed by Dunn’s comparison test.
A value of p < 0.05 was considered statistically significant.
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